These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

302 related articles for article (PubMed ID: 32557741)

  • 1. Clinical profile of non-alcoholic fatty liver disease in nonobese patients.
    Lum JHM; Cheah MCC; Leow WQ; Wan WK; Lim TKH; Chow WC; Chang JPE; Goh GBB
    J Gastroenterol Hepatol; 2021 Jan; 36(1):257-261. PubMed ID: 32557741
    [TBL] [Abstract][Full Text] [Related]  

  • 2. APRI: a simple bedside marker for advanced fibrosis that can avoid liver biopsy in patients with NAFLD/NASH.
    Kruger FC; Daniels CR; Kidd M; Swart G; Brundyn K; van Rensburg C; Kotze M
    S Afr Med J; 2011 Jun; 101(7):477-80. PubMed ID: 21920102
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Non-obese non-alcoholic fatty liver disease (NAFLD) in Asia: an international registry study.
    Tan EX; Lee JW; Jumat NH; Chan WK; Treeprasertsuk S; Goh GB; Fan JG; Song MJ; Charatcharoenwitthaya P; Duseja A; Imajo K; Nakajima A; Seki Y; Kasama K; Kakizaki S; Lesmana LA; Zheng KI; Zheng MH; Koh CJ; Ho KY; Goh KL; Wong VW; Dan YY
    Metabolism; 2022 Jan; 126():154911. PubMed ID: 34648769
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identifying Nonalcoholic Fatty Liver Disease Advanced Fibrosis in the Veterans Health Administration.
    Patel YA; Gifford EJ; Glass LM; Turner MJ; Han B; Moylan CA; Choi S; Suzuki A; Provenzale D; Hunt CM
    Dig Dis Sci; 2018 Sep; 63(9):2259-2266. PubMed ID: 29779083
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Steatosis severity affects the diagnostic performances of noninvasive fibrosis tests in nonalcoholic fatty liver disease.
    Joo SK; Kim W; Kim D; Kim JH; Oh S; Lee KL; Chang MS; Jung YJ; So YH; Lee MS; Bae JM; Kim BG
    Liver Int; 2018 Feb; 38(2):331-341. PubMed ID: 28796410
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Obesity Modifies the Performance of Fibrosis Biomarkers in Nonalcoholic Fatty Liver Disease.
    Qadri S; Ahlholm N; Lønsmann I; Pellegrini P; Poikola A; Luukkonen PK; Porthan K; Juuti A; Sammalkorpi H; Penttilä AK; D'Ambrosio R; Soardo G; Leeming DJ; Karsdal M; Arola J; Kechagias S; Pelusi S; Ekstedt M; Valenti L; Hagström H; Yki-Järvinen H
    J Clin Endocrinol Metab; 2022 Apr; 107(5):e2008-e2020. PubMed ID: 34971370
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Suboptimal performance of simple noninvasive tests for advanced fibrosis in Chinese patients with nonalcoholic fatty liver disease.
    Xun YH; Fan JG; Zang GQ; Liu H; Jiang YM; Xiang J; Huang Q; Shi JP
    J Dig Dis; 2012 Nov; 13(11):588-95. PubMed ID: 23107446
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Accuracy of Noninvasive Fibrosis Scores to Detect Advanced Fibrosis in Patients With Type-2 Diabetes With Biopsy-proven Nonalcoholic Fatty Liver Disease.
    Singh A; Gosai F; Siddiqui MT; Gupta M; Lopez R; Lawitz E; Poordad F; Carey W; McCullough A; Alkhouri N
    J Clin Gastroenterol; 2020; 54(10):891-897. PubMed ID: 32168133
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Diagnostic Accuracy of Noninvasive Fibrosis Models to Detect Change in Fibrosis Stage.
    Siddiqui MS; Yamada G; Vuppalanchi R; Van Natta M; Loomba R; Guy C; Brandman D; Tonascia J; Chalasani N; Neuschwander-Tetri B; Sanyal AJ;
    Clin Gastroenterol Hepatol; 2019 Aug; 17(9):1877-1885.e5. PubMed ID: 30616027
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Validation of the FIB4 index in a Japanese nonalcoholic fatty liver disease population.
    Sumida Y; Yoneda M; Hyogo H; Itoh Y; Ono M; Fujii H; Eguchi Y; Suzuki Y; Aoki N; Kanemasa K; Fujita K; Chayama K; Saibara T; Kawada N; Fujimoto K; Kohgo Y; Yoshikawa T; Okanoue T;
    BMC Gastroenterol; 2012 Jan; 12():2. PubMed ID: 22221544
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Assessment of liver fibrosis using non-invasive screening tools in individuals with diabetes mellitus and metabolic syndrome.
    Shaji N; Singhai A; Joshi R
    J Assoc Physicians India; 2022 Apr; 70(4):11-12. PubMed ID: 35443467
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characteristics of non-alcoholic steatohepatitis among lean patients in Japan: Not uncommon and not always benign.
    Tobari M; Hashimoto E; Taniai M; Ikarashi Y; Kodama K; Kogiso T; Tokushige K; Takayoshi N; Hashimoto N
    J Gastroenterol Hepatol; 2019 Aug; 34(8):1404-1410. PubMed ID: 30590868
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Noninvasive fibrosis tools in NAFLD: validation of APRI, BARD, FIB-4, NAFLD fibrosis score, and Hepamet fibrosis score in a Portuguese population.
    Rigor J; Diegues A; Presa J; Barata P; Martins-Mendes D
    Postgrad Med; 2022 May; 134(4):435-440. PubMed ID: 35332833
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Simple non-invasive fibrosis scoring systems can reliably exclude advanced fibrosis in patients with non-alcoholic fatty liver disease.
    McPherson S; Stewart SF; Henderson E; Burt AD; Day CP
    Gut; 2010 Sep; 59(9):1265-9. PubMed ID: 20801772
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical, anthropometric, biochemical, and histological characteristics of nonobese nonalcoholic fatty liver disease patients of Bangladesh.
    Alam S; Gupta UD; Alam M; Kabir J; Chowdhury ZR; Alam AK
    Indian J Gastroenterol; 2014 Sep; 33(5):452-7. PubMed ID: 25023045
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevalence of Nonalcoholic Steatohepatitis-Associated Cirrhosis in the United States: An Analysis of National Health and Nutrition Examination Survey Data.
    Kabbany MN; Conjeevaram Selvakumar PK; Watt K; Lopez R; Akras Z; Zein N; Carey W; Alkhouri N
    Am J Gastroenterol; 2017 Apr; 112(4):581-587. PubMed ID: 28195177
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Modified AST to platelet ratio index improves APRI and better predicts advanced fibrosis and liver cirrhosis in patients with non-alcoholic fatty liver disease.
    Huang C; Seah JJ; Tan CK; Kam JW; Tan J; Teo EK; Kwek A; Wong YJ; Tan M; Ang TL; Kumar R
    Clin Res Hepatol Gastroenterol; 2021 Jul; 45(4):101528. PubMed ID: 33268036
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of NAFLD and fibrosis in obese patients - a comparison of histological and clinical scoring systems.
    Schmitz SM; Kroh A; Ulmer TF; Andruszkow J; Luedde T; Brozat JF; Neumann UP; Alizai PH
    BMC Gastroenterol; 2020 Aug; 20(1):254. PubMed ID: 32758151
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Liver fibrosis markers and all cause mortality in people with type 2 diabetes: A population based study (The Ayrshire Diabetes Outcomes Cohort (ADOC) Study).
    Collier A; Curran C; Cameron L; Wild SH; Byrne CD
    Diabetes Obes Metab; 2023 Sep; 25(9):2659-2668. PubMed ID: 37311724
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The development of the pediatric NAFLD fibrosis score (PNFS) to predict the presence of advanced fibrosis in children with nonalcoholic fatty liver disease.
    Alkhouri N; Mansoor S; Giammaria P; Liccardo D; Lopez R; Nobili V
    PLoS One; 2014; 9(8):e104558. PubMed ID: 25121514
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.